No Data
Wuzhou Zhongheng Group Subsidiary Selected in Traditional Chinese Medicine Procurement
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary participated in the national Chinese Patent Medicine procurement alliance centralized bulk purchasing non-quote representative products is expected to be selected.
On February 24, Gelonghui reported that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that its holding subsidiary, Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. (referred to as "Wuzhou Pharmaceutical"), participated in the national Chinese Patent Medicine procurement alliance centralized bulk procurement work. Recently, according to the announcement issued by the national Chinese Patent Medicine joint procurement office titled "Public Announcement of Proposed Selected and Non-Quote Representative Products for Centralized Procurement by the National Chinese Patent Medicine Procurement Alliance," Wuzhou Pharmaceutical's product, thrombosis injection (freeze-dried), is proposed to be selected as a non-quote representative product for this national centralized bulk procurement by the Chinese Patent Medicine procurement alliance.
Even After Rising 5.6% This Past Week, Guangxi Wuzhou Zhongheng GroupLtd (SHSE:600252) Shareholders Are Still Down 19% Over the Past Five Years
Overview of the restricted stock release for A-shares | February 11.
According to the Zhitong Finance APP, on February 11, two listed companies had their restricted stocks released, with a total market value of approximately 63.2781 million yuan. The specific situation of the restricted stock release today is as follows: Stock abbreviation Stock code Restricted stock type Released stock quantity Guangxi Wuzhou Zhongheng Group 600252 Stock-based Incentive Restricted circulation 10.5848 million Kejingyuan 301372 Extended restricted lock-up period Circulation 1.1 million.
Guangxi Wuzhou Zhongheng Group Co., Ltd. 2024 Annual Results Forecast Announcement
Product quantity and price have both declined, coupled with impairments in goodwill and intangible Assets. Guangxi Wuzhou Zhongheng Group expects a loss of 0.2 billion to -0.4 billion yuan in 2024 | Interpretations.
① Guangxi Wuzhou Zhongheng Group released its annual performance forecast for 2024, expecting a net loss of 0.22 billion yuan to -0.43 billion yuan, with the non-recurring net income also expecting a loss of 0.2 billion yuan to -0.4 billion yuan. ② Despite the performance pressure, Guangxi Wuzhou Zhongheng Group simultaneously announced multiple measures to maintain the company's stock price, including stock cancellations, share repurchases, and voluntary locks by major shareholders.
Lacklustre Performance Is Driving Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
